378 related articles for article (PubMed ID: 24673717)
1. Lower dosing of enteric-coated mycophenolate sodium (Myfortic) can achieve target mycophenolic acid exposure rapidly in most Chinese renal transplant patients: a pilot study.
Yin H; Qiu K; Hu XP; Li XB; Wang W; Liu LH; Zhang XD
Int J Clin Pract Suppl; 2014 Apr; (181):31-7. PubMed ID: 24673717
[TBL] [Abstract][Full Text] [Related]
2. Which is more suitable for kidney transplantation at the early post-transplantation phase in China - low dosing or standard dosing of enteric-coated mycophenolate sodium?
Ding C; Xue W; Tian P; Ding X; Pan X; Xiang H; Tian X; Li Y; Zheng J
Int J Clin Pract Suppl; 2014 Apr; (181):10-6. PubMed ID: 24673714
[TBL] [Abstract][Full Text] [Related]
3. Cyclosporine A and tacrolimus combined with enteric-coated mycophenolate sodium influence the plasma mycophenolic acid concentration - a randomised controlled trial in Chinese live related donor kidney transplant recipients.
Huang HF; Yao X; Chen Y; Xie WQ; Shen-Tu JZ; Chen JH
Int J Clin Pract Suppl; 2014 Apr; (181):4-9. PubMed ID: 24673713
[TBL] [Abstract][Full Text] [Related]
4. Development and validation of limited sampling strategies for the estimation of mycophenolic acid area under the curve in adult kidney and liver transplant recipients receiving concomitant enteric-coated mycophenolate sodium and tacrolimus.
Pawinski T; Luszczynska P; Durlik M; Majchrzak J; Baczkowska T; Chrzanowska M; Sobiak J; Glyda M; Kuriata-Kordek M; Kamińska D; Krajewska M; Klinger M
Ther Drug Monit; 2013 Dec; 35(6):760-9. PubMed ID: 24192641
[TBL] [Abstract][Full Text] [Related]
5. Evalutation of mycophenolic acid systemic exposure by limited sampling strategy in kidney transplant recipients receiving enteric-coated mycophenolate sodium (EC-MPS) and cyclosporine.
Capone D; Tarantino G; Kadilli I; Polichetti G; Basile V; Federico S; Sabbatini M
Nephrol Dial Transplant; 2011 Sep; 26(9):3019-25. PubMed ID: 21317409
[TBL] [Abstract][Full Text] [Related]
6. Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure.
Tett SE; Saint-Marcoux F; Staatz CE; Brunet M; Vinks AA; Miura M; Marquet P; Kuypers DR; van Gelder T; Cattaneo D
Transplant Rev (Orlando); 2011 Apr; 25(2):47-57. PubMed ID: 21190834
[TBL] [Abstract][Full Text] [Related]
7. A prospective analysis of the effects of enteric-coated mycophenolate sodium and mycophenolate mofetil co-medicated with a proton pump inhibitor in kidney transplant recipients at a single institute in China.
Xu L; Cai M; Shi BY; Li ZL; Li X; Jin HL
Transplant Proc; 2014 Jun; 46(5):1362-5. PubMed ID: 24935300
[TBL] [Abstract][Full Text] [Related]
8. A single-centre, open-label, prospective study of an initially short-term intensified dosing regimen of enteric-coated mycophenolate sodium with reduced cyclosporine A exposure in Chinese live-donor kidney transplant recipients.
Cai L; Zeng F; Liu B; Wei L; Chen Z; Jiang J
Int J Clin Pract Suppl; 2014 Apr; (181):23-30. PubMed ID: 24673716
[TBL] [Abstract][Full Text] [Related]
9. No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study.
Rissling O; Glander P; Hambach P; Mai M; Brakemeier S; Klonower D; Halleck F; Singer E; Schrezenmeier EV; Dürr M; Neumayer HH; Budde K
Br J Clin Pharmacol; 2015 Nov; 80(5):1086-96. PubMed ID: 25913040
[TBL] [Abstract][Full Text] [Related]
10. The proton pump inhibitor pantoprazole and its interaction with enteric-coated mycophenolate sodium in transplant recipients.
Kofler S; Wolf C; Shvets N; Sisic Z; Müller T; Behr J; Sohn HY; Vogeser M; Shipkova M; Meiser B; Steinbeck G; Reichart B; Kaczmarek I
J Heart Lung Transplant; 2011 May; 30(5):565-71. PubMed ID: 21256049
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and pharmacodynamics of intensified versus standard dosing of mycophenolate sodium in renal transplant patients.
Glander P; Sommerer C; Arns W; Ariatabar T; Kramer S; Vogel EM; Shipkova M; Fischer W; Zeier M; Budde K
Clin J Am Soc Nephrol; 2010 Mar; 5(3):503-11. PubMed ID: 20150450
[TBL] [Abstract][Full Text] [Related]
12. Standard dose enteric-coated mycophenolate sodium (myfortic) delivers rapid therapeutic mycophenolic acid exposure in kidney transplant recipients.
Sumethkul V; Na-Bangchang K; Kantachuvesiri S; Jirasiritham S
Transplant Proc; 2005 Mar; 37(2):861-3. PubMed ID: 15848557
[TBL] [Abstract][Full Text] [Related]
13. Enteric-coated mycophenolate sodium given in combination with tacrolimus has a lower incidence of serious infections in Asian renal-transplant recipients compared with mycophenolate mofetil.
Feng JJ; Zhang LW; Zhao P; Bow LM; Tian J
Int J Clin Pract Suppl; 2015 May; (183):1-7. PubMed ID: 26176848
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and variability of mycophenolic acid from enteric-coated mycophenolate sodium compared with mycophenolate mofetil in de novo heart transplant recipients.
Hummel M; Yonan N; Ross H; Miller LW; Sechaud R; Balez S; Koelle EU; Gerosa G;
Clin Transplant; 2007; 21(1):18-23. PubMed ID: 17302587
[TBL] [Abstract][Full Text] [Related]
15. Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil.
Arns W; Breuer S; Choudhury S; Taccard G; Lee J; Binder V; Roettele J; Schmouder R
Clin Transplant; 2005 Apr; 19(2):199-206. PubMed ID: 15740555
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the exposure of mycophenolate mofetil and enteric-coated mycophenolate sodium in recipients of kidney-pancreas transplantation.
Belliere J; Esposito L; Gandia P; Duffas JP; Sallusto F; Cardeau-Desangles I; Del Bello A; Rostaing L; Kamar N
Ann Transplant; 2014 Feb; 19():76-81. PubMed ID: 24509827
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics of mycophenolic acid : a comparison between enteric-coated mycophenolate sodium and mycophenolate mofetil in renal transplant recipients.
de Winter BC; van Gelder T; Glander P; Cattaneo D; Tedesco-Silva H; Neumann I; Hilbrands L; van Hest RM; Pescovitz MD; Budde K; Mathot RA
Clin Pharmacokinet; 2008; 47(12):827-38. PubMed ID: 19026038
[TBL] [Abstract][Full Text] [Related]
18. Long-term dosing patterns of enteric-coated mycophenolate sodium or mycophenolate mofetil with tacrolimus after renal transplantation.
Langone A; Shihab F; Pankewycz O; Doria C; Wiland A; McCague K; Chan L
Clin Transplant; 2014 Sep; 28(9):961-7. PubMed ID: 24893821
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of mycophenolate sodium (EC-MPS) co-administered with cyclosporine in the early-phase post-kidney transplantation.
Stracke S; Shipkova M; Mayer J; Keller F; Zarghom A; Yang L; Henne-Bruns D; Wieland E
Clin Transplant; 2012; 26(1):57-66. PubMed ID: 21299636
[TBL] [Abstract][Full Text] [Related]
20. Randomized crossover study to assess the inter- and intrasubject variability of morning mycophenolic acid concentrations from enteric-coated mycophenolate sodium and mycophenolate mofetil in stable renal transplant recipients.
Tedesco-Silva H; Felipe CR; Park SI; Pinheiro-Machado PG; Garcia R; Slade A; Schmouder R; Medina-Pestana JO
Clin Transplant; 2010; 24(4):E116-23. PubMed ID: 20047618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
